Safety and efficacy of human gingiva-derived mesenchymal stem cells in patients with type 1 diabetes: a double-blind, randomized, placebo-controlled, phase 1 trial.
A phase 1 trial tested stem cells derived from gum tissue in type 1 diabetes patients, finding improvements in remaining beta-cell function and reduced insulin requirements at 12 weeks, with no increase in adverse events compared to placebo.
A plain-English summary of the study's own findings — we don't add our own claims or interpretation. Read the full paper for the complete methods and results, and apply your own clinical judgement.
Read the full study at the sourceRelated CPD from Vital Pulp
Managing the Pregnant Dental Patient
Confident, evidence-based dental care from the first trimester to the postpartum period
The Recall — the month's most significant new dental research, summarised. Free.
Browse The Recall